Zai Lab FY2023 product revenue $266.7M (+25% YoY); VYVGART launch drives 2024 outlook >$70M

Zai Lab Ltd

2023-FY EPS reported -$0.35 revenue$266,719,000

Product revenue $266.7M (+25% YoY; +31% CER); net loss narrowed to $334.6M from $443.3M.
VYVGART launched Sept 2023; 2023 revenue $10M; ~1,000 patients treated in Jan 2024; 2024 guidance >$70M.
ZEJULA $168.8M (+16% YoY); OPTUNE $47.0M (flat); QINLOCK $19.2M (+29%); NUZYRA $21.7M (+316%).
Cash $807.6M (Dec 31, 2023) vs $1.0B year prior; R&D down, SG&A up on VYVGART launch.
Targeting profitability by end of 2025; regulatory submissions expected for 4 new products in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zai Lab Ltd reported the year ended December 31, 2023 results: revenue $266.7 million, net income $334.6 million, EPS loss per ordinary share attributable to common stockholders of $0.35 (or loss per American Deposit Share ("ADS") of $3.4.

Period: the year ended December 31, 2023
Revenue: $266.7 million
Net income: $334.6 million
EPS: loss per ordinary share attributable to common stockholders of $0.35 (or loss per American Deposit Share ("ADS") of $3.4
Result: reported results

Exact text from the filing

by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates – Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate (CER) – VYVGART ® (efgartigimod alfa injection) was launched in September 2023 in

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001628280-24-007217

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.